KIN101 is a potent RNA viral inhibitor with IC50s of 2 μM, >5 μM for influenza virus and Dengue virus (DNV), respectively. KIN101, an isoflavone agonist of IRF-3 dependent signaling, induces IRF-3 nuclear translocation. KIN101 has broad-spectrum activity against RNA viruses[1][2].
KIN 101 (10 μM; 24 hours) causes a significant decrease in the NP protein abundance[1].KIN 101 (10 μM; 18 hours) shows a >1 log decrease in HCV RNA levels[1].KIN 101 (0.01, 0.1, 1, 10, 100 μM) has a significant and dose-dependent effect on the formation of foci and has an IC50 of 0.2 μM[1].KIN 101 (5, 10, 20, 50 μM; 4 hours) causes a dose-dependent decrease in influenza virus infection in MRC5 cells[1].KIN 101 results in a significant increase in the levels of ISGs as well as other proteins downstream of IRF activation such as RIG-I and MDA5[1].KIN101 (0.1-100 μM; 18 hours) shows the antiviral activity against hepatitis C virus (HCV)[2].
[1]. Bedard KM, et al. Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses. J Virol. 2012 Jul;86(13):7334-44.
[2]. Shawn P. Iadonato, et al. Anti-viral compounds, pharmaceutical compositions and methods of use thereof. US20160122312A1.